{"id":3721,"date":"2022-08-26T14:30:12","date_gmt":"2022-08-26T12:30:12","guid":{"rendered":"https:\/\/www.labex-lipstic.fr\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/"},"modified":"2022-08-26T14:51:03","modified_gmt":"2022-08-26T12:51:03","slug":"epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr","status":"publish","type":"equipesrecherche","link":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/","title":{"rendered":"Epigenetics, epidemiology and personalized treatment in hematological malignancies &#8211; Epi2THM (ex SAPHIHR)"},"content":{"rendered":"\r\n<p>La d\u00e9r\u00e9gulation des m\u00e9canismes \u00e9pig\u00e9n\u00e9tiques est une caract\u00e9ristique remarquable des h\u00e9mopathies malignes telles que les leuc\u00e9mies aigu\u00ebs my\u00e9loblastiques et les lymphomes. Des alt\u00e9rations somatiques r\u00e9currentes de facteurs \u00e9pig\u00e9n\u00e9tiques et \u00e9pitranscriptomiques clefs ont mis en \u00e9vidence leur importance dans l\u2019expression et la fonction des g\u00e8nes li\u00e9s \u00e0 l\u2019initiation et \u00e0 la progression des ces cancers. Nos projets sont d\u00e9di\u00e9s \u00e0 l\u2019\u00e9tude de protagonistes majeurs de la r\u00e9gulation \u00e9pig\u00e9n\u00e9tique et \u00e9pitranscriptomique, de leur pertinence pronostique et de leur possible ciblage th\u00e9rapeutique. Une grande part de ces travaux concernent l\u2019\u00e9valuation de leur implication oncog\u00e9nique via l\u2019inflammation, la signalisation lipidique ou l\u2019ob\u00e9sit\u00e9.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>La d\u00e9r\u00e9gulation des m\u00e9canismes \u00e9pig\u00e9n\u00e9tiques est une caract\u00e9ristique remarquable des h\u00e9mopathies malignes telles que les leuc\u00e9mies aigu\u00ebs my\u00e9loblastiques et les lymphomes. Des alt\u00e9rations somatiques r\u00e9currentes de facteurs \u00e9pig\u00e9n\u00e9tiques et \u00e9pitranscriptomiques clefs ont mis en \u00e9vidence leur importance dans l\u2019expression et la fonction des g\u00e8nes li\u00e9s \u00e0 l\u2019initiation et \u00e0 la progression des ces cancers. Nos [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":[],"financeurs":[],"categoriesvillesequipes":[117],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Epigenetics, epidemiology and personalized treatment in hematological malignancies - Epi2THM (ex SAPHIHR) - Labex Lipstic<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epigenetics, epidemiology and personalized treatment in hematological malignancies - Epi2THM (ex SAPHIHR) - Labex Lipstic\" \/>\n<meta property=\"og:description\" content=\"La d\u00e9r\u00e9gulation des m\u00e9canismes \u00e9pig\u00e9n\u00e9tiques est une caract\u00e9ristique remarquable des h\u00e9mopathies malignes telles que les leuc\u00e9mies aigu\u00ebs my\u00e9loblastiques et les lymphomes. Des alt\u00e9rations somatiques r\u00e9currentes de facteurs \u00e9pig\u00e9n\u00e9tiques et \u00e9pitranscriptomiques clefs ont mis en \u00e9vidence leur importance dans l\u2019expression et la fonction des g\u00e8nes li\u00e9s \u00e0 l\u2019initiation et \u00e0 la progression des ces cancers. Nos [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/\" \/>\n<meta property=\"og:site_name\" content=\"Labex Lipstic\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-26T12:51:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/\",\"url\":\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/\",\"name\":\"Epigenetics, epidemiology and personalized treatment in hematological malignancies - Epi2THM (ex SAPHIHR) - Labex Lipstic\",\"isPartOf\":{\"@id\":\"https:\/\/www.labex-lipstic.fr\/en\/#website\"},\"datePublished\":\"2022-08-26T12:30:12+00:00\",\"dateModified\":\"2022-08-26T12:51:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.labex-lipstic.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c9quipes de recherche\",\"item\":\"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Epigenetics, epidemiology and personalized treatment in hematological malignancies &#8211; Epi2THM (ex SAPHIHR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.labex-lipstic.fr\/en\/#website\",\"url\":\"https:\/\/www.labex-lipstic.fr\/en\/\",\"name\":\"Labex Lipstic\",\"description\":\"Site de Labex Lipstic\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.labex-lipstic.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epigenetics, epidemiology and personalized treatment in hematological malignancies - Epi2THM (ex SAPHIHR) - Labex Lipstic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/","og_locale":"en_US","og_type":"article","og_title":"Epigenetics, epidemiology and personalized treatment in hematological malignancies - Epi2THM (ex SAPHIHR) - Labex Lipstic","og_description":"La d\u00e9r\u00e9gulation des m\u00e9canismes \u00e9pig\u00e9n\u00e9tiques est une caract\u00e9ristique remarquable des h\u00e9mopathies malignes telles que les leuc\u00e9mies aigu\u00ebs my\u00e9loblastiques et les lymphomes. Des alt\u00e9rations somatiques r\u00e9currentes de facteurs \u00e9pig\u00e9n\u00e9tiques et \u00e9pitranscriptomiques clefs ont mis en \u00e9vidence leur importance dans l\u2019expression et la fonction des g\u00e8nes li\u00e9s \u00e0 l\u2019initiation et \u00e0 la progression des ces cancers. Nos [&hellip;]","og_url":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/","og_site_name":"Labex Lipstic","article_modified_time":"2022-08-26T12:51:03+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/","url":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/","name":"Epigenetics, epidemiology and personalized treatment in hematological malignancies - Epi2THM (ex SAPHIHR) - Labex Lipstic","isPartOf":{"@id":"https:\/\/www.labex-lipstic.fr\/en\/#website"},"datePublished":"2022-08-26T12:30:12+00:00","dateModified":"2022-08-26T12:51:03+00:00","breadcrumb":{"@id":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/epigenetics-epidemiology-and-personalized-treatment-in-hematological-malignancies-epi2thm-ex-saphihr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.labex-lipstic.fr\/en\/"},{"@type":"ListItem","position":2,"name":"\u00c9quipes de recherche","item":"https:\/\/www.labex-lipstic.fr\/en\/equipes-de-recherche\/"},{"@type":"ListItem","position":3,"name":"Epigenetics, epidemiology and personalized treatment in hematological malignancies &#8211; Epi2THM (ex SAPHIHR)"}]},{"@type":"WebSite","@id":"https:\/\/www.labex-lipstic.fr\/en\/#website","url":"https:\/\/www.labex-lipstic.fr\/en\/","name":"Labex Lipstic","description":"Site de Labex Lipstic","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.labex-lipstic.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/equipesrecherche\/3721"}],"collection":[{"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/equipesrecherche"}],"about":[{"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/types\/equipesrecherche"}],"author":[{"embeddable":true,"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/comments?post=3721"}],"version-history":[{"count":4,"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/equipesrecherche\/3721\/revisions"}],"predecessor-version":[{"id":3725,"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/equipesrecherche\/3721\/revisions\/3725"}],"wp:attachment":[{"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/media?parent=3721"}],"wp:term":[{"taxonomy":"financeurs","embeddable":true,"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/financeurs?post=3721"},{"taxonomy":"categoriesvillesequipes","embeddable":true,"href":"https:\/\/www.labex-lipstic.fr\/en\/wp-json\/wp\/v2\/categoriesvillesequipes?post=3721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}